Skip to main content

Apyx Medical Corp

corporate_fare Company Profile

Apyx Medical Corp

APYX·NASDAQ·Industrial Applications And Services·CIK 0000719135

The company is a surgical aesthetics company that develops innovative products for cosmetic and hospital surgical markets. Its key products include the Helium Plasma Platform Technology products, Renuvion and J-Plasma, and the AYON Body Contouring System. Renuvion and J-Plasma provide surgeons with controlled heat for tissue. AYON is an FDA-cleared, surgeon-designed body contouring system that integrates fat removal, closed-loop contouring, and Renuvion's tissue contraction and electrosurgical capabilities. The company also uses its expertise in unique waveforms through OEM agreements with other medical device manufacturers. On May 13, 2025, the company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for AYON. It completed a soft launch of AYON and commenced its commercial launch in September 2025. AYON is designed as an all-in-one system for comprehensive body contouring, integrating advanced modalities to perform multiple functions. These functions include infiltration, dual aspiration for simultaneous users, ultrasound-assisted liposuction, electrocoagulation for excess tissue removal, volume enhancement capabilities, and Renuvion treatment for loose and lax skin. On October 13, 2025, the company submitted a 510(k) premarket notification to the FDA for AYON's label expansion to include power liposuction.

Apyx Medical Corp (NASDAQ:APYX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 18 items for APYX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for APYX spans 10-Q, DEF 14A, 8-K, 10-K.

Recent high-impact activity:

  • Apyx Medical Posts $14M in Third-Quarter Sales
  • Apyx Medical Q2 Revenue Climbs 22% to $13.9M, Full-Year Guidance Reaffirmed
  • Apyx Medical Proposes New Share Incentive Plan with 9.5% Potential Dilution
  • Apyx Medical Appoints Stavros Vizirgianakis as Executive Chairman, Grants $1.9M in RSUs
  • Apyx Medical Study Shows Up to 81.8% Cellulite Improvement with Combined Avéli and Renuvion

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$52.84M
Net Income
-$11.21M
Op. Cash Flow
-$8M
Free Cash Flow
-$9.12M
Gross Profit
$33.04M
Operating Income
-$6.45M
Cash & Equivalents
$31.74M
Total Debt
$34.85M
Debt / Equity
2.40×
Net Margin
-21.2%
Shares Outstanding
41.79M sh
Source: 10-K · filed 2026-03-10 · accession 0001437749-26-007471

Short Interest & Short Volume

2.08 days to cover

FINRA reported short interest of 245,424 shares in APYX as of the October 30, 2026 settlement, a 14.8% increase from the prior period — about 2.1 days to cover at its recent average daily volume. On November 20, 2026, 11.7% of APYX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)245,424 shares as of October 30, 2026
Change vs prior period▲ 14.8%
Days to cover2.08 at avg daily volume of 118,106
Daily short volume (FINRA facilities)11.7% of 47,972 shares on November 20, 2026
5-day average short volume13.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$2.39
52-week range · as of 2026-08-06 $1.7 – $5.08
Market cap
$101.1M
Volume
100.1K (0.7× avg)
3-mo avg 138.7K
Live data · 2026-11-22 03:05 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed APYX - Latest Insights

APYX
Nov 05, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.67
Real-time Price: $2.39 info
Change: -$0.2817 (-11%) info
Market Cap: $101.098M info
APYX
Aug 06, 2026, 5:01 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.88
Real-time Price: $2.39 info
Change: -$1.49 (-38%) info
Market Cap: $101.098M info
APYX
Jun 26, 2026, 4:13 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $4.50
Real-time Price: $2.39 info
Change: -$2.11 (-47%) info
Market Cap: $101.098M info
APYX
Jun 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.21
Real-time Price: $2.39 info
Change: -$1.82 (-43%) info
Market Cap: $101.098M info
APYX
May 21, 2026, 4:33 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.25
Real-time Price: $2.39 info
Change: -$1.86 (-44%) info
Market Cap: $101.098M info
APYX
May 21, 2026, 4:23 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.25
Real-time Price: $2.39 info
Change: -$1.86 (-44%) info
Market Cap: $101.098M info
APYX
May 21, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.79
Real-time Price: $2.39 info
Change: -$1.40 (-37%) info
Market Cap: $101.098M info
APYX
May 14, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.84
Real-time Price: $2.39 info
Change: -$1.45 (-38%) info
Market Cap: $101.098M info
APYX
May 11, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.78
Real-time Price: $2.39 info
Change: -$1.39 (-37%) info
Market Cap: $101.098M info
APYX
May 11, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.78
Real-time Price: $2.39 info
Change: -$1.39 (-37%) info
Market Cap: $101.098M info
APYX
May 07, 2026, 4:55 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.38
Real-time Price: $2.39 info
Change: -$0.990 (-29%) info
Market Cap: $101.098M info
APYX
May 07, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.34
Real-time Price: $2.39 info
Change: -$0.950 (-28%) info
Market Cap: $101.098M info
APYX
Mar 10, 2026, 1:15 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.53
Real-time Price: $2.39 info
Change: -$1.14 (-32%) info
Market Cap: $101.098M info
APYX
Mar 10, 2026, 1:11 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $3.57
Real-time Price: $2.39 info
Change: -$1.17 (-33%) info
Market Cap: $101.098M info
APYX
Mar 10, 2026, 7:05 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $3.60
Real-time Price: $2.39 info
Change: -$1.21 (-34%) info
Market Cap: $101.098M info
APYX
Mar 10, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.60
Real-time Price: $2.39 info
Change: -$1.21 (-34%) info
Market Cap: $101.098M info
APYX
Mar 06, 2026, 7:32 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $3.26
Real-time Price: $2.39 info
Change: -$0.870 (-27%) info
Market Cap: $101.098M info
APYX
Jan 12, 2026, 8:02 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.55
Real-time Price: $2.39 info
Change: -$1.16 (-33%) info
Market Cap: $101.098M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets